title: [EFFECT OF LONGIDAZE ON MICROBIAL LANDSCAPE OF CERVICAL CANAL AND UTERINE CAVITY DURING THERAPY OF WOMEN WITH CHRONIC NONSPECIFIC ENDOMETRITIS AND UTERUS MYOMA].
abstract: OBJECTIVE
  Evaluation of microbiological effectiveness of longidaze preparation use during therapy of active non-specific endometritis in women with uterus myoma.
  
  
  METHODS
  2 groups of women were formed by a method of random selection. The first was composed of patients with active chronic endometritis, that had received standard etiotropic antibacterial therapy. The second included patients, that had received longidaze in addition to the standard therapy. Therapy effectiveness evaluation was carried out based on the analysis of microbial landscape of cervical canal and uterine cavity 2 months after the therapy during phase I of the menstrual cycle.
  
  
  RESULTS
  Non-plasma-coagulating staphylococci, enterococci and anaerobes were established to be present predominately in the examined women of both the first and the second group.
  
  
  CONCLUSIONS
  The application of longidaze in combination with antibacterial therapy results in the most significant improvement of microbial landscape of cervical canal and uterine cavity.
authors.forename: N A
authors.initials: NA
authors.lastname: Troshina
authors.forename: I I
authors.initials: II
authors.lastname: Dolgushin
authors.forename: V F
authors.initials: VF
authors.lastname: Dolgushina
authors.forename: L I
authors.initials: LI
authors.lastname: Bakhareva
authors.forename: I V
authors.initials: IV
authors.lastname: Kurnosenko
authors.forename: T V
authors.initials: TV
authors.lastname: Nadvikova
mesh_terms: D000328:Adult; D002584:Cervix Uteri / Q000382:microbiology / Q000473:pathology; D004716:Endometritis / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D016983:Enterococcus; D005260:Female; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000008:administration & dosage*; D007889:Leiomyoma / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D011108:Polymers / Q000008:administration & dosage*; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology; D013210:Staphylococcus; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology
chemical_list: D011108:Polymers; D006821:Hyaluronoglucosaminidase; C000597018:Longidaza